58.09

0.07% -0.04

Ionis Pharmaceuticals Inc (IONS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$58.13

Offen:

$58.36

24-Stunden-Volumen:

2.31M

Relative Volume:

0.81

Marktkapitalisierung:

$9.65B

Einnahmen:

$1.06B

Nettoeinkommen (Verlust:

$-326.58M

KGV:

-27.63

EPS:

-2.1022

Netto-Cashflow:

$-977.73M

1W Leistung:

-4.85%

1M Leistung:

+5.48%

6M Leistung:

-26.88%

1J Leistung:

-2.12%

1-Tages-Spanne:

$57.78

$58.96

1-Wochen-Bereich:

$57.47

$61.77

52-Wochen-Spanne:

$50.01

$86.74

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Firmenname

Ionis Pharmaceuticals Inc

Sektor

Healthcare (1074)

Branche

Biotechnology (600)

Telefon

(760) 931-9200

Adresse

2855 GAZELLE COURT, CARLSBAD, CA

Mitarbeiter

1,402

Twitter

@ionispharma

Nächster Verdiensttermin

2026-07-29

Neueste SEC-Einreichungen

IONS's Discussions on Twitter

Compare IONS vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IONS Ionis Pharmaceuticals Inc	58.09	9.76B	1.06B	-326.58M	-977.73M	-2.1022
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-21	Eingeleitet	Canaccord Genuity	Buy
2026-04-10	Fortgesetzt	Raymond James	Outperform
2026-01-28	Fortgesetzt	Barclays	Overweight
2025-10-08	Hochstufung	JP Morgan	Neutral → Overweight
2025-09-26	Hochstufung	Goldman	Sell → Neutral
2025-09-03	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2025-07-31	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2025-07-01	Hochstufung	Barclays	Equal Weight → Overweight
2025-04-07	Eingeleitet	H.C. Wainwright	Buy
2025-03-31	Eingeleitet	Redburn Atlantic	Neutral
2024-08-02	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2024-07-24	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-07-16	Fortgesetzt	Jefferies	Buy
2024-06-14	Hochstufung	Bernstein	Underperform → Mkt Perform
2024-04-10	Hochstufung	Wolfe Research	Peer Perform → Outperform
2024-01-02	Hochstufung	BofA Securities	Neutral → Buy
2023-10-23	Hochstufung	BofA Securities	Underperform → Neutral
2023-09-29	Eingeleitet	Raymond James	Strong Buy
2023-07-31	Hochstufung	Citigroup	Neutral → Buy
2023-06-07	Fortgesetzt	Piper Sandler	Overweight
2023-05-04	Hochstufung	Citigroup	Sell → Neutral
2023-03-21	Eingeleitet	Bernstein	Underperform
2022-12-21	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2022-09-09	Fortgesetzt	Morgan Stanley	Overweight
2022-07-18	Fortgesetzt	Oppenheimer	Outperform
2022-03-31	Fortgesetzt	Piper Sandler	Overweight
2022-03-01	Eingeleitet	Citigroup	Sell
2022-03-01	Eingeleitet	Guggenheim	Buy
2022-02-01	Herabstufung	BofA Securities	Buy → Underperform
2021-12-14	Hochstufung	William Blair	Mkt Perform → Outperform
2021-05-07	Hochstufung	UBS	Sell → Neutral
2021-03-01	Hochstufung	Barclays	Underweight → Equal Weight
2020-12-16	Eingeleitet	UBS	Sell
2020-12-15	Hochstufung	Cowen	Market Perform → Outperform
2020-09-14	Fortgesetzt	JP Morgan	Neutral
2020-09-02	Eingeleitet	The Benchmark Company	Hold
2020-06-01	Fortgesetzt	Oppenheimer	Outperform
2020-05-13	Eingeleitet	RBC Capital Mkts	Outperform
2020-03-05	Eingeleitet	Citigroup	Buy
2019-12-13	Eingeleitet	Oppenheimer	Outperform
2019-11-13	Eingeleitet	BofA/Merrill	Buy
2019-11-07	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2019-09-10	Hochstufung	Bernstein	Mkt Perform → Outperform
2018-08-08	Bestätigt	Stifel	Hold
2018-08-07	Bestätigt	Stifel	Hold
2018-05-08	Herabstufung	Evercore ISI	Outperform → In-line
2017-10-06	Fortgesetzt	Goldman	Sell
2017-08-17	Eingeleitet	Evercore ISI	Outperform
2017-08-09	Bestätigt	Stifel	Hold
2017-03-10	Herabstufung	Goldman	Neutral → Sell
2016-12-28	Bestätigt	BMO Capital Markets	Outperform
2016-12-27	Bestätigt	Leerink Partners	Mkt Perform

Alle ansehen

Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten

Aug 20, 2026

Ionis Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:IONS) - MarketBeat

Aug 20, 2026

Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026 - BioSpace

Aug 20, 2026

IONS Looks 26.4% Overvalued on GF Value™ - GuruFocus

Aug 20, 2026

Why Is Ionis Pharmaceuticals (IONS) Pushing RG-6299 Into A Pivotal Phase III Trial? - Sahm

Aug 20, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) Rating Increased to Hold at BMO Capital Markets - MarketBeat

Aug 20, 2026

Eagle Health Investments LP Acquires New Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Aug 20, 2026

DCF Advisers LLC Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Aug 20, 2026

Edmond DE Rothschild Holding S.A. Makes New Investment in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Aug 20, 2026

Great Lakes Advisors LLC Acquires Shares of 66,924 Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Aug 20, 2026

Aug 19, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) Earns Market Perform Rating from Analysts at BMO Capital Markets - MarketBeat

Aug 19, 2026

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For We - Benzinga

Aug 19, 2026

IONS Initiates Coverage On BMO Capital -- Price Target Announced at $60 - GuruFocus

Aug 19, 2026

BMO initiates Ionis Pharmaceuticals stock at Market Perform, PT $60 By Investing.com - Investing.com Canada

Aug 19, 2026

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm

Aug 19, 2026

Aug 18, 2026

IONS Looks 24.0% Overvalued on GF Value™ - GuruFocus

Aug 18, 2026

TimesSquare Capital Management LLC Takes $48.69 Million Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Aug 18, 2026

Grandfield & Dodd LLC Invests $2.94 Million in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Aug 18, 2026

Aug 17, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 17, 2026

Familial Amyloid Polyneuropathy Market - Future Market Insights

Aug 17, 2026

Ionis Pharma (IONS): FDA Catalysts, Accelerating Revenue And A Path To 2028 Cash-flow Breakeven - RTTNews

Aug 17, 2026

Piper Sandler Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $94 - Moomoo

Aug 17, 2026

Ionis Pharmaceuticals (IONS) Stock Analysis: Exploring a 56% Potential Upside in Biotech Innovation - DirectorsTalk Interviews

Aug 17, 2026

Aug 16, 2026

Ionis Pharmaceuticals Inc (HAM:ISI) Stock Price, Trades & News - GuruFocus

Aug 16, 2026

Ionis Pharmaceuticals Trades at 10.9x Sales as Pipeline Optimism Clashes With Valuation Reality - finance.biggo.com

Aug 16, 2026

Ionis (IONS) Stock Looks Like A Bargain On Value But Full On Sales - Yahoo Finance

Aug 16, 2026

Empowered Funds LLC Increases Stock Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat

Aug 16, 2026

ETFs Investing in Ionis Pharmaceuticals, Inc. Stocks - TradingView

Aug 16, 2026

Aug 15, 2026

Ionis Pharmaceuticals (IONS) Has A $92 Fair Value Narrative, Is The Stock A Bargain? - Yahoo Finance

Aug 15, 2026

IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval - stocktwits.com

Aug 15, 2026

Aug 14, 2026

Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? - The Motley Fool

Aug 14, 2026

Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? - The Motley Fool

Aug 14, 2026

Aug 12, 2026